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Metal-based anticancer drugs are pivotal in the fight against cancer pathologies. Since 1978 cis-
platin was licensed for medical treatment of a wide number of tumor pathologies(1). However its 
chemiotherapic use is strongly limited by many and severe side effects and acquired tumor 
resistance. Since these limitations could be overcome by other metal complexes, in the last thirty 
years  ruthenium compounds have been tested showing a remarkable antitumoral and antimetastatic 
activity associated with a lower toxicity. A hexacoordinate Ru(III) complex (NAMI-A) is currently 
undergoing advanced clinical evaluation (2). 
All data indicate that NAMI-A acts as a pro-drug, but the integrity of ruthenium complexes is 
essential to store the cytotoxic activity. In this scenario the condition of administration of ruthenium 
drugs are crucial to exploit their anticancer activity (3). In the last years innovative strategies have 
been produced to vehicle ruthenium ions in tumor cells like aggregates. This study aims to 
incorporate the ruthenium complexes in the inner aqueous compartment of liposomes and to test 
biological properties of two NAMI-A like pyridine derivatives. Specifically, we have investigated 
the pyridine derivatives of the sodium-compensated analogue of NAMI-A, Na[trans-
RuCl4(pyridine)(DMSO)] (NAMI-Pyr) and Na[trans-RuCl4(Pytri)(DMSO)] (NAMI-Pytri).  
In thelatter complex the pyridine ligand is functionalized with a sugar moiety so as to increase 
biocompatibility and the ability to cross the cell membrane. The stability of the complexes was 
studied and compared in solution at different pH following UV-VIS spectra. Lipid formulations 
based on Egg PC were prepared adding Cholesterol, DSPE-PEG2000  joining molar ratio 57/38 /5% 
w/w respectively in MeOH/CHCl3 (50/50 v/v) mixture and hydrated with 0.9% w/w of NaCl.  
 
 
 
 
 
 
 
 
This composition was selected to reproduce analog supramolecular aggregates in clinical use to 
vehicle doxorubicin (Doxil). Ruthenium complexes were loaded into liposomes using the passive 
equilibration loading method. Full drug containing liposomes were structurally characterized by 
dynamic light scattering (DLS) measurements. Data indicate the formation of stable aggregates with 
size and shape in the right range for in vivo applications. The amount of encapsulated ruthenium 
complexes was quantified by means of ICP-AES. Stability and drug release properties of ruthenium 
containing liposomes were confirmed in buffer. The growth inhibitory effects of both liposomal and 
free complexes drug were tested on prostate cancer cells (PC3).  
Preliminary results show high cytotoxic effect of ruthenium complexes delivered by supramolecular 
aggregates with respect to free complexes drug. 
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